Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression.
|
12374981 |
2002 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The recent finding of overexpression of the polycomb group transcriptional repressor EZH2 in prostate cancer raises the possibility that transcriptional regulation at the chromatin level may play a role in the development of the metastatic phenotype and suggests new avenues of exploration with respect to patient stratification and therapeutics.
|
12450788 |
2002 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to aggressive prostate cancer.
|
14500907 |
2003 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
When these results are considered together with published data on EZH2 and on the E2F3 control protein pRB, we conclude that the pRB-E2F3-EZH2 control axis may have a critical role in modulating aggressiveness of individual human prostate cancer.
|
15184867 |
2004 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ezh2 levels are increasingly elevated during prostate cancer progression.
|
15684044 |
2005 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, our results suggest that genetic variations of the EZH2 gene are not responsible for the linkage of 7q to aggressive prostate cancer.
|
16015586 |
2005 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our goal was to evaluate the gene copy number and expression alterations of EZH2 in prostate cancer.
|
16575874 |
2006 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For the first time, we provide images of human prostate carcinoma metastasis precursor cells isolated from blood and shown to overexpress both BMI1 and Ezh2 oncoproteins.
|
16963837 |
2006 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EZH2 promotes proliferation and invasion of prostate cancer cells, which can account for the correlation between EZH2 expression levels and an adverse prostate cancer prognosis.
|
17252556 |
2007 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
EZH2 expression increases during prostate cancer progression, whereas BMI-1 and SIRT1 are not well investigated.
|
18637271 |
2007 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
EZH2 mRNA expression density in the metastatic prostate cancer group was significantly higher than in the control (p=0.023) and localized prostate cancer groups (p=0.019).
|
18159594 |
2007 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The protein EZH2 is overexpressed in disseminated prostate cancer, implicating a role of PcG complexes in tumor progression.
|
17134822 |
2007 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma.
|
18406871 |
2008 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase polycomb group (PcG) protein, which has been implicated in the process of cellular differentiation and cancer progression for both breast and prostate cancer.
|
17453341 |
2008 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cytoplasmic EZH2 expression levels correlate with nuclear EZH2 expression in prostate cancer samples.
|
18095286 |
2008 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of the polycomb group protein enhancer of zeste homologue 2 (EZH2) occurs in diverse malignancies, including prostate cancer, breast cancer, and glioblastoma multiforme (GBM).
|
19934320 |
2009 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of EZH2 protein has been associated with biological malignancy of prostate cancer and several other cancers.
|
18619895 |
2009 |
Prostate carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
|
20479932 |
2010 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.
|
20622896 |
2010 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of the transcriptional repressor EZH2 has been reported to be associated with poor prognosis in various malignancies including breast cancer and prostate cancer.
|
19901851 |
2010 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
By using multiple cell lines, and examining overexpression and knockdown of EZH2 concurrently, a broad view of EZH2's role in prostate cancer was achieved.
|
20087897 |
2010 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using an Affymetrix cDNA microarray analysis, we investigated the expression of MSMB, CRISP3, androgen receptor (AR), KLK3 and Enhancer of Zeste Homologue-2 (EZH2) in tissue from prostate cancer patients receiving (n=17) or not receiving (n=23) ADT before radical prostatectomy.
|
20680031 |
2010 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since Ezh2 is overexpressed and acts as an oncogene in PCa, it has been proposed as a bona fide target of PCa therapy.
|
20478051 |
2010 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While the test for the prostate cancer antigen 3 (PCA3) is commercially available, the aim of our research was to test other putative urine markers in multiplex settings (AMACR (α-methylacyl-CoA racemase), EZH2 (enhancer of zeste homolog 2), GOLM1 (golgi membrane protein 1), MSMB (microseminoprotein, β), SPINK1 (serine peptidase inhibitor) and TRPM8 (transient receptor potential cation channel, subfamily M, member 8)).
|
21788966 |
2011 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results link two major pathways in prostate cancer by providing two additional and complementary Myc-regulated mechanisms by which EZH2 upregulation occurs and is enforced during prostatic carcinogenesis.
|
21941025 |
2011 |